Biotech Values

[oc631]

All talk that GILD was malevolent for not pursuing a Sovaldi + Daclatasvir partnership with BMY should immediately cease.

I agree. I respect GILD's right to develop in-house and some people were unwilling to give ledipasvir a chance to prove itself in the sofosbuvir combination. What's inexcusable was not advancing the interferon-based option for patients in GT2/GT3.

Sofosbuvir reads out like a miracle drug, and it is. But by the power of open-label studies, a small (comparator) cohort of Sofo/PegRiba in GT3 had a 78% SVR rate. This means adding interferon took away from the Sofo/Riba combos efficacy. Go figure.